International audienceThe aim of the present study was to test the effects of hydroxyurea (HU) therapy on clinical, hematological and hemorheological parameters in adult patients with sickle cell anemia (SCA). Hematological and hemorheological parameters were measured in 28 SCA patients before HU therapy (i.e., baseline) and at 6, 12 and 24 months of treatment. RBC deformability was determined by ektacytometry at 30 Pa. RBC aggregation properties were investigated by light-backscatter method. Blood viscosity was measured at 225 s-1 by a cone-plate viscometer. The rates of vaso-occlusive crises and acute chest syndrome were lower at 1 and 2 years of HU therapy compared to baseline. The proportion of patients with leg ulcers tended to decreas...
Clinical experience with hydroxyurea for patients with sickle cell disease (SCD) has been accumulati...
grantor: University of Toronto27 patients with hemoglobin SS were treated with HU, for (me...
The use of hydroxyurea (HU) can improve the clinical course of sickle cell disease. However, several...
International audienceThe aim of the present study was to test the effects of hydroxyurea (HU) thera...
International audienceInflammation and oxidative stress play a key role in the pathophysiology of si...
Hydroxyurea (HU) enhances the synthesis of fetal hemoglobin (HbF) and can improve the clinical cours...
BACKGROUND: The development of therapies for sickle cell disease has received special attention, par...
Sickle cell is a hereditary disease affecting more than 100,000 people in the United States alone th...
Although hemoglobin SC (HbSC) disease is usually considered less severe than sickle cell anemia (SCA...
Background: The development of therapies for sickle cell disease has received special attention, par...
International audienceHydroxyurea (HU) has been suggested to act as a nitric oxide (NO) donor in sic...
OBJECTIVE: Sickle cell anemia and the interaction S/Beta thalassemia differ in hematological values ...
International audienceThis review focuses on the contribution of abnormal blood rheology in the path...
Clinical experience with hydroxyurea for patients with sickle cell disease (SCD) has been accumulati...
grantor: University of Toronto27 patients with hemoglobin SS were treated with HU, for (me...
The use of hydroxyurea (HU) can improve the clinical course of sickle cell disease. However, several...
International audienceThe aim of the present study was to test the effects of hydroxyurea (HU) thera...
International audienceInflammation and oxidative stress play a key role in the pathophysiology of si...
Hydroxyurea (HU) enhances the synthesis of fetal hemoglobin (HbF) and can improve the clinical cours...
BACKGROUND: The development of therapies for sickle cell disease has received special attention, par...
Sickle cell is a hereditary disease affecting more than 100,000 people in the United States alone th...
Although hemoglobin SC (HbSC) disease is usually considered less severe than sickle cell anemia (SCA...
Background: The development of therapies for sickle cell disease has received special attention, par...
International audienceHydroxyurea (HU) has been suggested to act as a nitric oxide (NO) donor in sic...
OBJECTIVE: Sickle cell anemia and the interaction S/Beta thalassemia differ in hematological values ...
International audienceThis review focuses on the contribution of abnormal blood rheology in the path...
Clinical experience with hydroxyurea for patients with sickle cell disease (SCD) has been accumulati...
grantor: University of Toronto27 patients with hemoglobin SS were treated with HU, for (me...
The use of hydroxyurea (HU) can improve the clinical course of sickle cell disease. However, several...